Page 6 - Pharma Sector

Dr Reddy's sees sharpest intra-day rally since Sept 2020; stock surges 8%

The stock gained 9 per cent in two days after the pharma company reported better-than-expected revenue growth in March quarter (Q4FY22).

Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483

Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days

Pfizer sets up drug development centre at Chennai's IIT Research Park

The centre integrates two essential functions under the export-oriented undertaking of Pfizer: Pharmaceutical Sciences (PharmSci) and Global Technology and Engineering (GT&E) Centre of Excellence.

Domestic branded generic formulations market can grow at 10-12%: Industry

Cadila Healthcare Chairman Pankaj Patel said the market can grow when there is overall growth

Govt wants to reduce compliance burden on pharma sector: Mansukh Mandaviya

Union Minister for Chemicals and Fertilizers Mansukh Mandaviya on Thursday said that the government wants to reduce the compliance-burden on the pharma industry for ease of doing business. Speaking as the chief guest at an Indian Drug Manufacturers' Association (IDMA) event here, Mandivya, who is also the Minister for Health and Family Welfare, said that the Narendra Modi-led government at the Centre is not only pro-poor and pro-farmer but industry-friendly as well. We want the ease of doing business for the industry and lessen the compliance burden on it. This is why we always carry out consultations with all stakeholders prior to the formulation of any policy or regulation (governing the pharma industry), Mandaviya said. The government is helping the industry by amending the Drugs and Cosmetics Act, 1940 and promoting Ease of Doing Business, he said, adding, We are involving the industry in decision-making processes. Also, through a series of webinars, the government has tried to

Bulk of pharma growth came from price hikes, shows data

The average increase in prices was 3.1 per cent in the past five years.

Demand for chronic drugs likely to rise 30% ahead of price hike

There would be a general rise in demand for chronic medicines as consumers would stock up ahead of a price rise

Cipla, Ipca Lab, Zydus Life to benefit most from drug price rise: Analysts

The recent price hike, analysts said, brings some respite for the industry facing multiple headwinds such as steep raw inflation, price erosion in the US market and higher freight costs.

Confident of getting EUA for use of Corbevax in 5-12 years: Biological E

Biological E Ltd on Wednesday expressed confidence over getting emergency use authorisation for use of its Corbevax anti-COVID vaccine in children in the age group of 5-12 years.

Govt earmarks Rs 500 cr for scheme to support pharma clusters, MSMEs

The government has earmarked Rs 500 crore for a scheme to provide support to the existing pharma clusters and MSMEs across the country to improve their productivity and sustainability

Lupin gets USFDA approval to market anti-epilepsy drug in US market

Drug firm Lupin on Friday said it has received approval from the US health regulator to market its anti-epilepsy drug Vigabatrin for Oral Solution in the American market.

Sensex sinks 769 pts, Nifty below 16,250; Titan, Maruti fall 5%, IT stks up

CLOSING BELL: Sectorally, only the Nifty IT index eked out gain on the NSE, rising 0.14 per cent

Lupin launches generic medication, to be manufactured in Nagpur, in US

Drug maker Lupin on Tuesday said it has launched Sevelamer Hydrochloride tablets (800 mg), used to treat hyperphosphatemia in patients with chronic kidney disease, in the US market

Pharma industry likely to grow to $130 billion by 2030: Industry leaders

'As India becomes an increasingly more important component for the global supply chain, that should benefit the industry going forward,' Sun Pharma Managing Director Dilip Shanghvi said

Expand PLI scheme for pharma to make it research-linked, says industry

So far 55 drug manufacturers have been selected under the PLI scheme for pharma.

Lab stocks scramble for new growth in India as Covid gains halve

Surging healthcare spending and demand for Covid tests led to multifold share-price gains for pathology firms globally during the pandemic

Natco Pharma consolidated net profit up 27% to Rs 80 crore in Dec quarter

The Hyderabad-based company had reported a net profit of Rs 63.4 crore in the October-December period of previous fiscal

Eco Survey 20-21: Foreign direct investment in pharma sees 'sudden spurt'

The increase in foreign investment in the pharma sector in 2020-21 is mainly on account of investments to meet Covid-19-related demands for therapeutics and vaccines, according to the Economic Survey

Current anti-Covid pills work well against Omicron, shows study

A new study has found the drugs behind the new pills to treat COVID-19 remain very effective against the Omicron variant of the virus in lab tests.The research has been published in the 'New England Journal of Medicine'.However, lab tests also showed that the available antibody therapies -- typically given intravenously in hospitals -- are substantially less effective against omicron than against earlier variants of the virus. Some antibodies have entirely lost their ability to neutralize omicron at realistic dosages.If the ability of the antiviral pills to combat omicron is confirmed in human patients, it would be welcome news. Public health officials expect the pills to become an increasingly common treatment for COVID-19 that will reduce the severity of the disease in at-risk patients and decrease the burden of the pandemic.For now, the pills remain in short supply during the current omicron wave, which has broken case records in the U.S. and other countries.The findings ...

USFDA pulls up Aurobindo Pharma for manufacturing lapses at API plant

The US Food and Drug Administration (USFDA) has issued a warning letter to Aurobindo Pharma for violating current good manufacturing practice norms at its Telangana-based plant.